

# Use of oral sarecycline as monotherapy and in combination with topical treatments in patients with acne: A post-hoc analysis of results from the Patient Reported Outcomes for Sarecycline Effectiveness and Safety (PROSES), a single-arm prospective cohort study

Hilary Baldwin MD,<sup>1</sup> Elizabeth Swanson MD,<sup>2</sup> Adam Friedman MD,<sup>3</sup> Joshua Zeichner MD,<sup>4</sup> Danielle Dubin MD,<sup>5</sup> Shanna Miranti MPAS, PA-C,<sup>6</sup> Raidah Salem PharmD, MBA,<sup>7</sup> Paul Tomondy PharmD,<sup>7</sup> Emmy Graber MD, MBA<sup>8,9</sup>

1. Acne Treatment and Research Center, Brooklyn, NY; 2. St. Luke's Children's Hospital, Boise, ID; 3. George Washington University School of Medicine and Health Sciences, Washington, DC; 4. Mount Sinai Hospital, New York, NY; 5. Icahn School of Medicine at Mount Sinai, New York, NY; 6. Riverchase Dermatology, Naples, FL; 7. Almirall, LLC, Malvern, PA; 8. The Dermatology Institute of Boston, Boston, MA; 9. Northeastern University, Boston, MA

## SYNOPSIS

- The American Academy of Dermatology (AAD) recommends that systemic antibiotics should be administered with benzoyl peroxide and/or other topical therapies.<sup>1</sup> PROSES, a single-arm, prospective, observational cohort study, enrolled 300 patients with facial non-nodular moderate-to-severe acne vulgaris (AV) who received oral sarecycline as part of usual care per clinician's judgment.<sup>2</sup>
- In this real-world study, there were no restrictions on the use of concomitant medications. Efficacy was assessed by Investigators' Global Assessment (IGA) at baseline and week 12.
- 121 evaluable patients received no concomitant medications and 124 received at least one topical agent.
- The percentages of patients in the monotherapy and combination treatment groups who achieved IGA of clear or almost clear at 12 weeks were 61.2% vs 57.2%, respectively (P=0.6033).

## OBJECTIVE

- To assess IGA success in patients administered sarecycline with and without concomitant acne medications.


## ACKNOWLEDGEMENTS AND DISCLOSURES

**Hilary Baldwin:** Advisory board member, consultant, and/or speaker for Almirall, Arcutis, Bausch, Bausch Health, Beiersdorf, Cutera, Dermavant, Galderma, Journey, Kenvue, La Roche Posay, L'Oréal, Nutrafol, Sanofi, Sun, and Tarsus. Investigator for Bausch, Cutera, and Galderma. **Elizabeth Swanson:** Advisor, consultant, and/or speaker for AbbVie, Almirall, Alphys, Arcutis, Boehringer Ingelheim, Castle, Chiesi, Galderma, Incyte, Johnson & Johnson, Leo, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, and Verrica. **Adam Friedman:** Advisory board member, consultant, and/or speaker for Arcutis, Galderma, Hoth Therapeutics, Johnson & Johnson, Kenvue, La Roche Posay, Leo Pharma, Lilly, Mino Labs, Microcures, Novartis, Pfizer, Regeneron/Sanofi, Takeda, UCB, and Zylto Therapeutics. Grants from AbbVie, Galderma, Incyte, Johnson & Johnson, Lilly, L'Oréal, Pfizer, and Regeneron/Sanofi. **Joshua Zeichner and Danielle Dubin:** No relevant disclosures. **Shanna Miranti:** Advisory board member, consultant, and/or speaker for Arcutis, Dermavant, EPI Health, Galderma, Incyte, Leo Pharma, Ortho Derm/Bausch, Sun Pharma, SwiftUSA, and Verrica. **Raidah Salem and Paul Tomondy:** Employees of Almirall LLC. **Emmy Graber:** Advisory board member, consultant, and/or speaker for Almirall, Beiersdorf, Cutera, Digital Diagnostics, Galderma, La Roche Posay, L'Oréal, Ortho Dermatologics, and WebMD. Investigator for Almirall and Ortho Dermatologics. Royalties from WoltersKluwer Health. Stock ownership in Digital Diagnostics. **This presentation was funded by Almirall LLC, Malvern, PA.**


## METHODS

- PROSES was carried out at 30 community dermatology practices in the United States between March 2021 and May 2022. Patients (N=300) ≥9 years old, with a confirmed diagnosis of facial non-nodular moderate-to-severe AV received oral sarecycline (60 mg, 100 mg, or 150 mg) as part of usual care.
- Efficacy was assessed by IGA with acne severity rated as 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe, at baseline and week 12. Data were evaluated with nonparametric statistics (sign-rank and Fisher's Exact tests).

## RESULTS



## RESULTS



## Conclusions

The efficacy of sarecycline in patients with moderate-to-severe AV is comparable in those who were or were not receiving concomitant non-oral antibiotic therapy. Results for individual agents combined with sarecycline should be viewed with some caution due to small sample sizes. Further, adherence to therapy was monitored for sarecycline but not for other acne treatments.

**REFERENCES:** 1. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol.* 2024;90(5):1006.e1-1006.e30; 2. Baldwin HE, Graber E, Harper JC, et al. Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study. *J Drugs Dermatol.* 2024;23(2):SF405634s12-SF405634s18.